Abstract
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.
©2016 American Association for Cancer Research.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
DNA Polymerase II / genetics*
-
Gene Expression Regulation, Neoplastic / drug effects
-
Germ-Line Mutation / genetics
-
Glioblastoma / drug therapy*
-
Glioblastoma / genetics*
-
Glioblastoma / pathology
-
Humans
-
Male
-
Neoplasm Proteins / biosynthesis
-
Poly-ADP-Ribose Binding Proteins
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / genetics*
Substances
-
Antibodies, Monoclonal, Humanized
-
Neoplasm Proteins
-
PDCD1 protein, human
-
Poly-ADP-Ribose Binding Proteins
-
Programmed Cell Death 1 Receptor
-
pembrolizumab
-
DNA Polymerase II
-
POLE protein, human